In Episode 746 of Power Athlete Radio, Dr. Adeel Khan dives into cutting-edge advancements in regenerative medicine, focusing on induced pluripotent stem cells ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions ...

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in a adults with Parkinson’s disease whose ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated th ...

ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and ...

Aspen Neuroscience, Inc. has successfully completed dose escalation and the first two cohorts of patients in the ASPIRO study, an ANPD001 Phase 1/2a clinical trial in Parkinson's Disease ...

Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the ...

The lab of Professor Peter Vangheluwe at KU Leuven is collaborating with SandboxAQ, an AI company, to expedite the discovery and testing of candidate drugs to restore the function of ATP10B, a protein ...

In addition to its CNS focus, Jupiter is evaluating opportunities in longevity and metabolic health. Emerging data suggests that JOTROL’s inhibition of NLRP3, when combined with GLP-1 treatments, ...

Loss of smell affects 1 in 4 people by their 50s and may signal neurological diseases Learn from an expert why this link exists and how being aware can aid in early diagnosis ...